News

Download PDF: 

prnewswire_surmodics_egen.pdf

HUNTSVILLE, Ala., July 27 /PRNewswire-FirstCall/ -- SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry and EGEN, Inc., a privately held biopharmaceutical company focused on developing nucleic acid (DNA and RNAi) therapeutics for the treatment of human diseases, are pleased to announce they have executed a continuation of their feasibility collaboration focused on long-term controlled release of siRNA complexes.

Download PDF: 

prnewswire_diatherix_std_panel.pdf

Tests provide rapid, accurate diagnosis of 10 STDs and Herpes Simplex 1 and 2

HUNTSVILLE, Ala., July 27 /PRNewswire/ - DIATHERIX Laboratories (www.DIATHERIX.com), adds a Sexually Transmitted Disease (STD) panel and Herpes Simplex Virus (HSV) panel to its line up of highly sensitive, rapid response diagnostic panels. The HSV panel identifies herpes simplex viruses 1 and 2 and the STD panel identifies 10 sexually transmitted diseases simultaneously, many of which cannot be accurately identified by current testing methods. These STD organisms, if not appropriately treated, can cause diseases such as syphilis, gonorrhoeae, chlamydia, bacterial vaginosis, etc. and may lead to blindness, infertility or complications during pregnancy.

Download PDF: 

htimes_synthetic_oil_spill_solution.pdf

By Paul Gattis

HUNTSVILLE, Ala. - How nice would it be if you could create something that would simply eat the oil that's polluting the Gulf of Mexico?

Don't laugh or roll your eyes. The ridiculous is becoming a reality.

"That is a goal," Huntsville scientist Lance Larka said. "That's what we want to do."

Download PDF: 

dayton_diatherix.pdf

Kettering Medical Center working with Alabama company to improve care, save money.

By Ben Sutherly
Staff Writer

KETTERING — Kettering Medical Center expects a partnership with an infectious disease diagnostic company to improve patient care and save the hospital money through more rapid diagnoses.

Download PDF: 

clarient_pulmotype.pdf

Clarient Insight Dx Pulmotype is the first commercial test launched following the recent acquisition of HudsonAlpha resident associate Applied Genomics Inc.  AGI developed Pulmotype and recently validated the test with a clinical study cohort of more than 1,000 patients.  The peer-reviewed results were published in the August 2009 edition of Modern Pathology.  A link to that study can be accessed at www.clarientinc.com/pulmotype.

Download PDF: 

clarient_acquires_applied_genomics.pdf

“We are extremely excited to expand our industry leading cancer characterization capabilities to the Huntsville area. Applied Genomics will add significant capabilities that fill a gap in our corporate offering. Clearly, having connectivity to the state of the art Hudson Alpha Institute and its genomic discovery capabilities was an attractive component in our search for the right development partner. We are enthusiastic about the short and long term opportunities of this deal.”
—Ron Andrews, chief executive officer, Clarient, Inc.